John Hancock Preferred Income Fund logo

John Hancock Preferred Income Fund (HPI)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
16. 11
-0.06
-0.3711%
$
434.3M Market Cap
- Div Yield
32,800 Volume
$ 16.17
Previous Close
Add Transaction
Day Range
16.11 16.23
Year Range
15.26 17.61
Want to track HPI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
HPI: Fiscal Dominance Could Challenge Ability To Deliver Attractive Real Returns

HPI: Fiscal Dominance Could Challenge Ability To Deliver Attractive Real Returns

The John Hancock Preferred Income Fund offers a 9.17% yield, blending preferred stocks and bonds for high current income. HPI's portfolio diverges from pure preferred stock funds, with over 40% in corporate bonds, impacting both yield and risk profile. The fund's distribution is mostly covered by net investment income and realized gains, but reliance on unrealized gains warrants monitoring.

Seekingalpha | 14 hours ago
HPI: This 9.7% Yielding Preferred Fund Is A Buy (Rating Upgrade)

HPI: This 9.7% Yielding Preferred Fund Is A Buy (Rating Upgrade)

John Hancock Preferred Income Fund is now rated a buy, trading at a 0.26% premium to NAV and offering a 9.7% yield. HPI's income-focused strategy leverages preferred securities and corporate bonds, with 59.94% investment-grade exposure and aggressive 38.64% leverage. Performance is poised to improve as interest rates decline, enhancing operating spreads and supporting higher valuations, especially with AI infrastructure-linked utilities exposure.

Seekingalpha | 3 months ago
Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development

Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development

Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HDV candidate ABI-6250 are expected to initiate by end of 2026, with interim catalysts ahead. ABI-6250 aims to be the first oral HDV therapy, addressing an unmet need with positive phase 1a data and a favorable safety profile supporting daily dosing.

Seekingalpha | 4 months ago
HPI: Stretched CEF Blending Corporate Bonds With Preferred Equity

HPI: Stretched CEF Blending Corporate Bonds With Preferred Equity

HPI is a leveraged CEF blending preferred equity and BBB/BB corporate bonds, with high financials exposure and 38% leverage, magnifying both gains and losses. Despite a 9% distribution, a significant portion is return of capital, making the true yield closer to 7-8%, not fully supported by income. Valuation is unattractive: HPI trades at NAV with tight credit spreads and high rates, leaving little upside and heightened downside risk in a downturn.

Seekingalpha | 1 year ago
HPI: This Preferred Stock Fund Has A Strange Portfolio

HPI: This Preferred Stock Fund Has A Strange Portfolio

The John Hancock Preferred Income Fund offers an 8.04% yield, but its portfolio is split between preferred stocks and corporate bonds, diverging from its stated strategy. The fund's share price has risen 24.18% over the past year, reducing its yield from 9.84% to 8.04%. The fund's net asset value has not kept up with the recent share price appreciation.

Seekingalpha | 1 year ago
HPI: This Fund Is Navigating The Current Environment Well, But It Is Pricy

HPI: This Fund Is Navigating The Current Environment Well, But It Is Pricy

The John Hancock Preferred Income Fund offers an attractive 8.88% yield, one of the highest among preferred stock funds. The fund's current yield may not keep up with rising living costs if held in a taxable account. The fund has outperformed its benchmark indices and has a relatively stable distribution history, but its portfolio allocation and valuation should be considered.

Seekingalpha | 2 years ago